EDITH PEREZ was named vice president and head of Genentech/Roche BioOncology U.S. Medical Affairs. Perez stepped down as vice chair of the Alliance for Clinical Trials in Oncology.
Perez’s primary focus at Genentech and Roche will be to develop and implement medical strategies to optimize the utilization of cancer medicines and to lead a broad spectrum of oncology medical affairs activities including phase IV trials, medical education, publications, medical communication, advisory boards, promotional material review and product launches.
She will remain a professor of medicine at the Mayo Clinic, where she will continue to pursue basic and translational research in breast cancer.
Perez has been a key Alliance leader since 2010, when she joined in planning and implementing the merger of three cooperative groups that created the Alliance.
In addition to her role as vice chair, she served as vice president of the Alliance Foundation. Perez also worked closely with the Alliance Patient Advocate Committee, serving as an advisor and facilitating the implementation of initiatives such as published plain-language summaries of Alliance studies for patients and the general public.
As the principal investigator of one of the landmark trials for the adjuvant treatment of breast cancer by using Herceptin in combination with chemotherapy, she helped paved the way for the 2005 discovery that changed how treatment is managed for patients with HER2-positive breast cancer.
She also holds positions with the American Association for Cancer Research, the American Society of Clinical Oncology, and NCI and continues to serve on the editorial boards of multiple academic journals and has authored more than 700 research articles and abstracts.
